Chairperson & Scientific Advisor
Professor Bengt Fadeel, M.D., Ph.D., is Head of the Molecular Toxicology Unit at the Institute of Environmental Medicine, Karolinska Institutet. He has long-standing experience in nanotoxicology with participation in several national and EU-funded projects. More recently, his team has focused on nano(bio)materials for drug delivery (nanomedicine). He is also Chair of the scientific panel of the Swedish national nanosafety platform, SweNanoSafe.
Chief Executive Officer & Founder
Dr. Sourav Pr. Mukherjee, Ph.D., has 14+ years’ of experience in immunology, toxicology, oncology, hematology, pulmonary research, in different positions at government regulatory agency (Health Canada), pharmaceutical industry (AstraZeneca), and many academic institutions in several countries. He has a broad range of experience in project management of many pan-European projects and trans-atlantic projects with many commercial and academic partners. He has strong expertise in different omics techniques/methods in proteomics and transcriptomics for the drug target finding, lead optimisation, mechanism of action finding, biomarker development etc., as well as in bioassay developments for the need of specific projects, also in PK/PD studies of different drugs, drug candidates and chemicals using in vitro, ex vivo, and in vivo models.
Collaborator, Scientific & Business Advisor
Prof. Roman Zubarev, Ph.D., is the Director of Proteomics and Chemical Proteomics Facility and Head of the Division of Physiological Chemistry I of Department of Medical Biochemistry and Biophysics (MBB) at Biomedicum, Karolinska Institutet. He is the winner of many international prestigious awards, viz., The Distinguished New Technologies Award (Venice, 2006), Curt Brunnée Award from International Mass Spectrometry Society (Prague, 2006), Gold medal from Russian Mass Spectrometry Society (2013) etc. He is a Board member & Executive Committee member of World Human Proteome Organization and Board member of Swedish Mass Spectrometry Society. He is the editorial board member and referee of many top journals and scientific funding bodies, viz. Molecular and Cellular Proteomics, Journal of Alzheimer’s Disease, Nature, Nature Methods, Anal Chem, JACS etc. He has authored over 300 peer review scientific publications in top journals and have eleven patents/ patent applications. He has worked in collaboration with many companies, e.g., Amgen, AstraZeneca, Oriflame, Thermo Fisher Scientific, SpectroSwiss, Biomotif etc. and Co-founded six innovation & consultancy companies based on his own research.
Chief Operating Officer
Dr. Sanchali Gupta Mukherjee, PhD, is the Chief Technical Officer at ISOREA AB. She has over 12 years’ experience in toxicology, oncology, cell and molecular biology with over 7+ years working experience in pharmaceutical companies in preclinical, translational research, as well as in CMC (Chemistry, Manufacturing, and Controls). Earlier she has worked as a Senior Scientist at Aprea Therapeutics AB in oncology research where she was primarily responsible for preclinical developments, as well as translational research for clinical trials and also worked closely with CMC team. Additionally, she was the primary contact point for in vivo studies by external CROs, co-contact point for external Clinical CROs (in USA) for translational studies in clinical trials. In her previous Scientist position at Sigrid Therapeutics AB, she worked on drug candidate synthesis, standardization, optimization, and efficacy testing. Additionally, Sanchali had standardized the synthesis protocol and worked with a CRO for scale-up of a drug candidate for Phase-1 clinical trial.
